NCT02129673

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: ViSci Ltd. · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension

Conditions

• Open Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	VS101 Insert Dose A	Sustained release of latanoprost into the eye
DRUG	VS101 Insert Dose B	Sustained release of latanoprost into the eye
DRUG	VS101 Insert Dose C	Sustained release of latanoprost into the eye
DRUG	Latanoprost 0.005% eye drops	Latanoprost 0.005% eye drops administered once daily on the eye

Timeline

• Start date: 2014-05-01
• Primary completion: 2017-05-01
• Completion: 2017-08-01
• First posted: 2014-05-02
• Last updated: 2018-03-14

Locations

1 site across 1 country: United States